A Message From the President |
|
Welcome to the March 2021 edition of the American Brachytherapy Society's BrachyBlast.
Just a quick update on our 2021 virtual annual meeting. The abstract submission deadline has now passed, and we have received a total of 150 abstracts. We also have finalized our plenary speaker sessions and will have two great speakers. Dr. Norm Coleman, from the NCI, and Dr. Harmer Brereton, at Geisinger Commonwealth School of Medicine. Our Chair of the Board, Dr. Petereit section provides more details on the topics and the speakers, I am grateful for his effort in organizing this session. The 2021 ABS Annual Meeting will be designed around the theme Innovations in a Time of Change. Scientific Program Chair Dr. Kristen Bradley along with Co-Chair, Dr. Timothy Showalter has worked hard along with the program committee putting together a program with new flavors and topics that you will find helpful for your current and future practice success. Our virtual platform is looking great and more descriptions will be provided, please mark your calendar to join the ABS 2021 Annual Meeting!
|
|
I want to thank those of you who have renewed your 2021 ABS membership. If you have not, you have until March 31. We are a small society that relies on individual members like you, who are committed to making an impact in the field of brachytherapy. I look forward to serving you as president for the 2nd half of my term and I am optimistic for a bright future for our specialty. I am grateful for your dedication and perseverance during this difficult time.
The ABS is celebrating March as Women’s History Month. We wanted to recognize of the women of the ABS (physicians, physicists, therapists, and nurses). Listen to our first Podcast as Dr. Beth Erikson speaks about her wonderful career story in brachytherapy, the Podcast was moderated by Dr. Catheryn Yashar. This is truly inspiring and I encourage you to listen to this conversation. #ThisIsBrachytherapy #brachytherapy #WomensHistoryMonth
Also, Dr. Mitch Kamrava's article in this Brachyblast titled #WomenWhoCurie provides an incredible historical story about the contribution of women to our field in early 1900 for use of radium for gynecologic cancers as well as women health disparity in terms of receiving appropriate gynecologic brachytherapy.
I want you to be aware of the AAPM has opened a public comment period (until April 16, 2021) of the ABS endorsed AAPM Task Group 303: MRI Implementation in gynecologic and prostate HDR brachytherapy - considerations from simulation to treatment. The TG report provides an introduction and rationale for MRI implementation in BT, a review of previous publications on topics including available applicators, clinical trials, previously published BT-related TG reports, and new image-guided recommendations beyond CT-based practices. The report describes MRI protocols and methodologies, including recommendations for the clinical implementation and logical consideration for MR imaging for HDR-BT. Given the evolution from prescriptive to risk-based QA, an example of risk-based analysis using MRI-based, prostate HDR-BT is presented. If you are an AAPM physics member, you can access this online, or please email me directly and I can share with you the report for your comments.
From the Radiation Safety Corner, Dr. Showalter has written an important reminder to measure accurately the length of the catheter length used in HDR brachytherapy. The recent event from the NRC webpage is an unfortunate example of this geographic miss of the target. I believe our physics members are aware of this source of error that will result in a medical event.
The article by Drs. Trombetta, Horne, Matani, and Lasorda is an exciting contribution about the reprised role of intravascular brachytherapy for coronary in-drug eluting stent restenosis. I recall the excitement of this modality to inhibit coronary restenosis in late 1990, in fact, I started my career developing IVBT Galileo 32P system at Guidant. The cardiovascular and vascular market has a great application for brachytherapy, and even when J&J announced the first success of the drug-eluting stent in the early 2000s, we expected IVBT will still have a role to play. I am glad IVBT is still a viable option over the last 20 years.
Regarding the annual election of board members, we had a slight delay in sending the voting link to our members, but we have plenty of time, the announcement will be sent out soon after the migration of the ABS servers this spring. This is an important upgrade to our outdated infrastructure. We plan another virtual Business meeting before or after the annual meeting to ensure this transition occurs.
Thank you,
Firas Mourtada, Ph.D.
ABS President
Follow Us on Twitter:
@fmourtad
|
|
The International Cancer Expert Corps (ICEC) and the ABS
Daniel G. Petereit, MD, FASTRO
C. Norman Coleman, MD, DSc (h.c.), FASTRO
|
|
I have had the opportunity to serve as a board member for both the ABS and the ICEC over the last few years. One of my motivations for serving on the ICEC has been to be a liaison with the ABS. The ICEC envisions a world in which everyone has access to interventions to prevent and treat cancer and symptoms using high-quality best practices for the local circumstances. Addressing, realizing, and sustaining this vision can benefit people everywhere because of the scientific, societal, humanitarian, diplomatic consequences of ICE see activities. It aims to build the capacity and capability of local practitioners within their community. The 2 project goals are s: strengthening the twinning program model and addressing technology gaps for access. Their strategic plan is well outlined on their website: iceccancer.org
Providing quality cancer care for low middle-income countries (LMICs) is a high priority. The ICEC twinning/mentorship program aligns with the ABS goals of 300 in 10 with training competent brachytherapy teams - especially in the management of advanced cervical cancer where the majority of these patients are treated, and with our NEXTGENBRACHY mentorship program.
The ABS International committee, under the leadership of Dr. Junzo Chino, has been in dialogue with the Bugando Medical Center (BMC) in Tanzania. The radiation oncology team at the BMC is seeking a partnership with the ABS to support radiation departmental needs. This includes access to resource materials such as the Journal of brachytherapy, and a partnership with ABS members to review cases and provide guidance. They are treating 6 cervical cancer patients a day and are currently using Point A dosimetry with a miniaturized HDR cobalt source. Their goal is to transition into CT and potentially MRI-based planning. As discussed in Dr. Chino’s editorial, “we are recruiting a group of ABS members to engage with the BMC for regular virtual site visits over the coming year, with an aim for an in-person visit when travel is safe”. Our goal in the next 2 years, once funding is secured, is to send senior-level brachytherapists to BMC to review their current treatment approach and better understand their clinical environment. Following this, we propose a “Surbhi Grover model”, where a younger brachytherpist would have the opportunity to spend 1 month or so at the BMC. This would be an example of reverse mentorship where the US brachytherapist would have the opportunity to learn from our BMC colleagues how they manage a high volume, cervical brachytherapy practice. There are several research opportunities with this partnership as well.
In the US, there are several brachytherapy curriculums that have been developed or are in development that we plan on sharing with our BMC colleagues. So, as we are moving 300 in 10 forward in the US to train more competent BT teams, we believe the BMC project could serve as a pilot site to assess 300 in 10 in a resource-limited cancer center where they manage the majority of cervical cancer patients worldwide.
We co-authors have worked together addressing cancer care disparities for almost 2 decades. Bringing cancer care to those without it is not an option and is a matter of those who regard “too hard” as an unacceptable answer. ICEC has a growing global network and recognizes the unique strengths of both academia and community practitioners. We share the vision of radiation oncology being a leader in global cancer care as what we do is essential to cure and palliation. We see this ICEC-ABS partnership as an opportunity for tremendous contributions, personal growth, and being able to look back and smile at Nelson Mandela’s wonderful observation “it always seems impossible until it is done”.
Dr. Norm Coleman, from the NCI and the senior scientific advisor to the ICEC, Dr. Harmer Brereton, at Geisinger Commonwealth School of Medicine and ICEC BOD member, will be 2 of our ABS plenary speakers. Dr. Coleman will further describe the ICEC mission and objectives, while Dr. Brereton will discuss how to successfully implement programs which is very timely with all our ABS initiatives. We are grateful that Dr. Coleman and Dr. Brereton agreed to share their wisdom, knowledge, and expertise with our ABS members.
|
|
Women in History Month
Beth Erickson, MD and Catheryn Yashar, MD
|
|
March is Women’s History Month. It is a time to honor the vital role of women throughout history and to celebrate the contributions of women in brachytherapy. Listen as Beth Erickson, MD shares her journey with Catheryn Yashar, MD, and the obstacles she faced along the way.
|
|
#WomenWhoCurie
Mitchell Kamrava, MD and Albert Chang, MD
on behalf of the Socioeconomic Committee
|
|
March is Women’s History Month and serves as an opportunity to recognize and celebrate women. Essential contributions to our field by women abound. There is one physician, who stands out, as she is credited with being the first physician in the world to use radium for gynecologic cancers. Margaret Cleaves (1848-1917) received her medical degree from the University of Iowa State University in 1873 and initially specialized in psychiatry. At the time, it was thought that gynecologic disorders precipitated insanity in women. She quickly challenged this prevailing idea and suggested female mental illness may instead have been related to “the endless monotony of the lives of the majority of women” and “too frequent childbearing”. Cleaves ended up leaving the field of psychiatry and entered the new discipline of radiation therapy. She was a true pioneer who realized that radium placed close to the tumor might be more penetrating, and therefore therapeutic, than x-rays. In 1903 Cleaves wrote in Medical Records that she inserted radium into the uterus of a woman with cervical cancer. This was a case “declared inoperable by the best surgical talent”. She inserted the tube of radium for a total of fifteen minutes over the course of two days. Over 100 years later brachytherapy is still an essential component in the curative treatment of cervical cancer!
Unfortunately, not all women are receiving this indispensable treatment. Even more troubling, black women are less likely to get brachytherapy as part of their treatment compared with non-black women (adjusted odds ratio 0.87 (95% CI 0.79-0.96). They also have higher all-cause mortality if they do not receive brachytherapy but no differences in survival if they receive brachytherapy. This research highlights the survival impact that a disparity in access to brachytherapy is having.
The reasons underlying this disparity are complex. Temkin et al published a wonderful review outlining a framework for understanding health disparities in gynecologic cancers. Alson et al also recently published a review on structural racism and its impact on reproductive health. They identify four domains of systemic racism that may affect health outcomes: civil rights laws and legal racial discrimination, residential segregation and housing discrimination, police violence, and mass incarceration. There are no simple solutions to achieving equity but progress can not be made without first acknowledging it and then moving forward with ideas to try to help.
Within the field of radiation oncology, The Society for Women in Radiation Oncology (SWRO) was established in 2017 as a platform to promote women in the field of radiation oncology. In honor of one of the most important contributors to radiation oncology, they launched the #WomenWhoCurie day which is now an impactful yearly tradition. We also need to remember the women that we treat and making sure all women who need it have access to life-saving radiation treatment - #NoWomanLeftBehind.
References
Knepper K and Donaldson SS: Women in Radiation Oncology and Radiation Physics. Chapter 9. In: A History of the Radiological Sciences. Radiation Oncology. R.A. Gagliardi and J. Frank Wilson, Eds., 1996 Radiology Centennial Inc. Reston, VA, 1996, pp. 231-262.
Cleaves M. Radium: with a preliminary note of radium rays in the treatment of cancer. Medical Record. 1910.
Alimena S, Yang D, Melamed A, et al. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol. 2019.
Alson J, Robinson W, Pittman L, et al. Incorporating measures of structural racism into population studies of reproductive health in the United States: a narrative review. Health Equity. 2021.
|
|
Importance of Accurate Catheter Length Information
During HDR Brachytherapy
Tim Showalter, MD, MPH
on behalf of the Patient Safety Corner
|
|
The importance of accurately measuring catheter length, and ensuring the correct information is entered in the brachytherapy treatment planning system, cannot be overstated in terms of impact on patient safety.
A recent event report posted to the NRC webpage provides one example of the effect of the entry of an incorrect catheter length in the treatment planning system. In this case, the treatment intent was to deliver a dose of 24 Gy to the target volume during ovarian cancer treatment with HDR brachytherapy using an Ir-192 source. An incorrect catheter treatment length entered into the treatment planning system resulted in 21.8 Gy delivered to the large bowel and 0 Gy delivered to the target volume.
Best practices to prevent the reoccurrence of such events include double-checks of catheter length measurements and entry of this information in treatment planning systems.
A related recent topic that has been shared with the Patient Safety Committee is the clinical implementation of a new afterloader design that features a position verification test for each channel. The intended purpose of this design element is likely to streamline the quality assurance process and reduce the potential for errors in catheter treatment length data entry in the treatment planning system. The position verification test involves the use of a pressure sensor at the end of the dummy cable to detect the end of each channel, with subsequent adjustment of the source position based on these measurements. Based upon this process, the dummy source cable position becomes as important as the source position based upon dependent position adjustment. Clinical use, therefore, represents a substantial transition from manual measurements and entry in the treatment planning system. The new system warrants attention to developing new procedures to ensure safety and quality, particularly in managing variation in source position among channels. We encourage ABS members who are evaluating how to incorporate position verification testing in their brachytherapy practice to contact the Patient Safety Committee to connect with other members interested in collaboration.
Whether with traditional manual measurements of channel length or with a new system with integrated position verification testing, a continued focus on accurate catheter length information is a vital component of safe brachytherapy practice that requires ongoing vigilance.
|
|
The Reprised Role of Intravascular Coronary Brachytherapy for
In-Stent, In-Stent Restenosis
Mark G. Trobetta, MD, Zacharry D. Horne, MD,
Hirsch Matani, MD and David Lasorda, DO
|
|
Discussions related to brachytherapy generally relate to the treatment of malignant diseases, however, our history reflects a tradition of brachytherapy use in benign diseases such as keloids, granulation tissue, and others as well (1-3).
In the late 1990s and early 2000s, intracoronary vascular brachytherapy (IVBT) barnstormed into the mainstream of interventional cardiology following the widespread use of intracoronary angioplasty, demonstrating up to 85% patency of stented and un-stented vessels (4,5). Despite the widespread generation of complimentary favorable data, the publishing of multiple textbooks, and even the founding of a dedicated journal, the development of drug-eluting stents (DES) brought an abrupt halt to IVBT(6). Well, not quite a complete stoppage……
Restenosis rates following the use of DES after angioplasty are established at approximately 15- 20% in multiple randomized clinical trials (7, 8). In the subgroups of those who fail first DES attempts, many patients can undergo a second stenting with a DES (and sometimes a third). For those persons who fail and have no alternative to live a symptom-free life (approximately 3-5% of restenosis patients), IVBT represents a valuable treatment option. Best Medical International (Springfield, VA, USA) manufactures the only device still made for IVBT: the Novoste Beta-Cath® system, which uses 90Sr/Yt to deliver an arbitrary dose of 18.4 Gy (for vessels less than 3.5 mm in diameter) or 23.0 Gy (for vessels 3.5 mm or greater in diameter). Recently published data demonstrated the safety of IVBT in a group of 134 high-risk patients, demonstrating a grade 3 or higher complication in less than 5% of patients (9). Another recently published study of 197 patients undergoing IVBT for multi-stent restenosis found that in comparison to patients not treated with IVBT after the percutaneous intervention, major adverse cardiac events at one year were decreased from 28.2% to 13.2% (10).
Procedurally, the lesion is identified during cardiac catheterization. The obstruction within a previously stented area is determined (or not) to be amenable to repeat stenting. In cases where repeat stenting is impossible, the vessel is prepared by angioplasty. Additionally, in cases where significant calculus plaque buildup precedes dilatation, pretreatment with ultrasound-based calcular fracture prior to angioplasty is performed. More than 50% of recurrent occlusions occur in stents that are under deployed. When the appropriate dilatation has been achieved, the linear beta source (90Sr) is introduced by the hydraulic system (Beta-Cath®). The dwell time, and therefore dose, is arbitrarily determined by luminal size. A luminal diameter of less than 3.5 mm receives a dose of 1840 cGy, while a luminal diameter of 3.5 mm or greater requires a dose of 2300 cGy. Dose delivery averages 4.5-6 minutes depending on prescription dose and source activity. The entire IVBT treatment adds approximately 10 minutes to the catheterization procedure with minimal side effects. An occasional patient will develop chest pain with source introduction, though in our experience, this is less than 5% of patients. Our own data in 99 high-risk patients treated show similar outcomes and prepublication sub-analysis shows a developing trend toward increasing vessel patency, which we expect may translate into life-changing results. It must be remembered that these patients are all considered “high risk”, in that, they have an unstable coronary vascular status and are at high risk for peri-catheterization death due to coronary vascular compromise, especially in the recurrently narrowed stent region. In the total patients treated to date, we experienced one intraprocedural death due to the development of an intracoronary thrombus in a 37-year-old male who had 7 prior stentings, including the twice stented area of IVBT.
It is unlikely that randomized Phase 3 data can be developed since these patients have no ethical alternative except supportive/palliative medical management and eventual short-term death. We believe that IVBT in patients with in-stent, in-stent restenosis and no viable long-term alternative be considered for IVBT.
1. Seegenschmiedt MH, Micke O, Muecke R, et al. Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. Br J Radiol July 15; 88 (1051). doi: 10.1259/bjr.20150080
2. Madu CN, Maschuzak MS, Steman DH, et al. High dose rate brachytherapy for the treatment of benign obstructive granulation tissue. Int J Radiat Oncol Biol Phys Vol. 63S 111; Oct DOI: https://doi.org/10.1016/j.ijrobp.2005.07.189
3. Taylor R and the Royal College of Radiologists: A review of the use of radiotherapy in the U.K. for the treatment of benign clinical conditions and benign tumors. Feb 2015. ISBN: 9789-1-905034-66-6. Ref No BFCO (15) 1.
4. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000; 10:2165-2171.
5. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001; 344:250-256.
6. Bailey SR. Drug-eluting stents have made brachytherapy obsolete. Curr Opin Cardiol. 2004 Nov;19(6):598-600.
7. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008; 118:1817-1827.
8. Stone GW, Ellis SG, O’Shaughnessy CD, et al. paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006; 295:1253-1263.
9. Ohri N, Sharma S, Kini A, et al. Intracoronary brachytherapy for instant restenosis of drug-eluting stents. Adv Radiat Oncol. 2016 Jan-Mar; 1(1):4-9.
10. Varghese MJ, Bhatheja S, Baber U, et al. Intravascular brachytherapy for the management of repeated multimetal-layered drug-eluting coronary stent restenosis. Circ Cardiovasc Interv. 2018 Oct; 11(10):e006832.
|
|
International Committee Corner
Junzo Chino, MD
on behalf of the International Committee
|
|
The International Committee of the American Brachytherapy Society has a mission to increase awareness and expand access to high-quality brachytherapy around the globe. To meet that goal, our primary resource is the knowledge and expertise of our committee members that represent the diversity of brachytherapy practitioners worldwide. Unfortunately, the COVID-19 pandemic has put a temporary hold on transcontinental observerships that are facilitated by the committee, however, there are several new initiatives in 2021 that have engaged the committee to leverage the skills of our members.
The first is work with the ICEC (The International Cancer Expert Corps, iceccancer.org) who is working with the Bugando Medical Center (BMC) in Mwanza, Tanzania – as described by Dr. Petereit. We are recruiting a group of ABS members to engage with the BMC for regular virtual site visits over the coming year, with an aim for an in-person visit when travel is safe.
A second initiative is aiding in the development of a brachytherapy training program in conjunction with RCC (Rayos Contra Cancer, rayoscontracancer.org), putting together a comprehensive educational platform to mentor a new generation of brachytherapists in Latin America. The committee is seeking a group of volunteers to aid in curriculum development, virtual teaching sessions, and other support of this worthy project. Interested members can fill a short questionnaire at the following link: https://forms.gle/V2GX2Ks7RVBF5uDx7
A third project is being developed in conjunction with the IBS (Indian Brachytherapy Society, indianbrachytherapy.org), aiming to produce a guide for the development of new brachytherapy programs in low-middle-income countries (LMIC).
For more information on any of these initiatives, or for opportunities to volunteer with the international committee activities, please contact either of the chairs of the committee (Junzo Chino, Chair – junzo.chino@duke.edu or Pranshu Mohindra, Vice Chair - pranshumohindra1@gmail.com). We would also like to invite any physicists interested in these projects to join the committee – your skills will be highly valued! Resident and Fellow engagement in these activities is also very much welcome and encouraged.
Here’s to a better 2021!
|
|
Consensus Statements - Call for Authors! |
|
Contemporary Image-Guided Cervical Cancer Brachytherapy: A Consensus Statement between the Society of Abdominal Radiology and the American Brachytherapy Society
This is an intersociety consensus statement with authors including members of the Society of Abdominal Radiology Uterine and Ovarian Cancer Disease Focused Panel (DFP) with published experience in cervical cancer brachytherapy imaging guidance and members from the American Brachytherapy Society (ABS) with expertise in GYN brachytherapy. This consensus statement summarizes contemporary cervical cancer brachytherapy workflow and the role of imaging for pre-treatment evaluation, implant assessment,
Please contact Melissa Pomerene by April 5, 2021, if you are interested in participating.
Approval Process of ABS Consensus Statements
In order to provide ABS members updates on standard brachytherapy management through the development of updated and/or new ABS consensus statements. We have updated our approval process of Consensus Statements.
The ABS Board of Directors (BOD) will select the topic, and senior and junior authors. The senior author will need to provide a list of publications and is required to have published on the topic of interest in the last 5 years. All proposed ABS consensus statements will include a summary paragraph detailing the subject matter and timeline. The ABS BOD requires that all authors who participate in these consensus statements are ABS members. It is recognized that contributing authors from other specialties will participate and are not required to be ABS members. If the proposed consensus statement is an update, the authors will need to reference the previous guidelines and summarize changes ( see attachment for a list of previous guidelines/statements). All ABS members will be notified through the ABS Blast of the proposed consensus statement for other interested co-authors to apply; a maximum of 10 authors will be selected. It is strongly encouraged that all authors, should have published or presented on the subject matter in the last 5 years. The timeline below details the process. Any controversies regarding authorship, subject content, or other issues will be resolved by the BOD consensus subcommittee.
Timeline Process:
- The ABS BOD will select the topic, junior and senior authors. ABS BOD will review the proposal for initial approval. Topics from non-board members will also be considered with ABS BOD approval.
- Notification to the ABS membership through the ABS Blast to identify the other 8 co-authors.
- Once final authorship is approved by the ABS BOD consensus sub-committee, the final document should be completed in 6 months and submitted to the President-elect or President for ABS BOD peer review by 2 members.
- Once the document is reviewed and approved by the ABS BOD, the document will be posted for “public comment” by the ABS membership for 30 days.
- Once the manuscript has been reviewed with additional edits incorporated, the authors will submit it to the Journal of Brachytherapy within 30 days.
|
|
We are pleased to announce the launch of Spot On Brachytherapy. This all-digital platform includes videos/podcasts focusing on brachytherapy while incorporating sections on clinical guidelines and practice development. For residents, a section has been developed in conjunction with ARRO. The platform also includes economic/coding resources, a physics section, and nursing resources to help start brachytherapy programs. We anticipate continued growth of this platform in the months and years to come. |
|
We're Getting Excited for #ABSBRACHY21 |
|
Registration is opening soon. Be sure to follow us on Facebook and Twitter for more Conference excitement.
|
|
LDR Prostate Brachytherapy: Common Mistakes and Tips for
High-Quality Implants
In this presentation, Dr. Orio, American Brachytherapy Society Past President and current Past Chairman of the Board, will highlight his tips and tricks to achieve a high-quality low-dose-rate prostate brachytherapy implant. Dr. Orio will review optimal patient selection criteria and anatomic considerations from treatment planning to isotope delivery. Dr. Orio will also review technical considerations, including the pros and cons of different implant philosophies. He will discuss his personal implant technique and the HELP (HDR Emulated Low dose rate Prostate brachytherapy) technique. And finally, Dr. Orio will review patient outcomes with an eye on techniques to improve outcomes and limit toxicities of treatment.
When: April 29, 2021
Time: 5:00 pm Eastern
|
|
This is just a reminder that your membership with the ABS has expired and your benefits end TODAY, Wednesday, March 31. If you’re still deciding whether or not to renew, or just haven’t gotten around to it yet, here's a reminder about all the great benefits that you receive:
- 300 in 10
- Develop and promote standards of education in brachytherapy through our annual meeting and Schools
- Support directly to market awareness campaigns highlighting the effectiveness of brachytherapy as part of the treatment course of many different types of cancer
- Improve Radiation Oncology reimbursement services for patients and providers
- Negotiate with CMS to advocate for fair payments for brachytherapy
- Advise the NRC in simpler regulatory language around brachytherapy
- Live webinars offering SA-CME and CME
- Networking opportunities during our Virtual Outreach Events (VOE) with leading brachytherapy practitioners
- Address medical events and quality assurance issues for practitioners by keeping members up-to-date on current regulations
- Enhance and facilitate international learning experiences by networking and communicating with other brachytherapy societies around the world
- Online access to scientific materials, including event recordings from prior meetings, including SA-CME sessions
|
|
Just Posted:
- TRUS Based Prostate HDR for Both the Beginner and Advanced User
- Overcoming Obstacles to your Brachytherapy Practice: Practical Tips to Optimize Your Practice
- The Medical Physics Nuts and Bolts of MR for GYN and Prostate
- CT/MRI Based HDR Prostate Brachytherapy
|
|
2020-2021 ABS Board of Directors |
|
Firas Mourtada, PhD, President
Ann Klopp MD, PhD, President Elect
Peter J. Rossi, MD, Vice President
Brett W. Cox, MD, Treasurer
Christopher L. Deufel, Secretary
Daniel G. Petereit, MD, Chairman of the Board
Peter F. Orio, III, DO, MS, Past Chairman of the Board
Directors-at-Large
Kristin Bradley, MD
Mitchell Kamrava, MD
Mira Keys, MD
Timothy Showalter, MD
|
|
|
|
|
|
|
